Novel 2-fluoropyridinyl analogs of FACH and biological evaluation of one potential radioligand for imaging of monocarboxylate transporters (MCTs) with PET

Objective: MCT1-4 are involved in several diseases, particularly in cancer. [18F]FACH has recently been developed as a novel MCT-targeting imaging agent (1), which could be used for monitoring MCT-based treatment approaches. With the aim to develop a similar potent radiotracer with higher brain permeability for future brain tumor studies, we designed structurally modified analogs of FACH possessing increased lipophilicity.

Methods: Two analogs of FACH (I and II) were synthesized by introduction of a 2-fluoropyridinyl moiety via Buchwald-Hartwig cross coupling reaction. Inhibition of MCT1 was measured by [14C]lactate uptake assay using rat brain endothelial cells and analog I with higher inhibition was selected to synthesize corresponding precursor used for radiofluorination by aromatic nucleophilic substitution. LogD7.4 of [18F]I was experimentally determined in the n-octanol-PBS system. In vitro autoradiography and dynamic PET studies of [18F]I were performed in CD-1 mice.

Results: The analogs I and II showed a moderate MCT1 inhibition with IC50 values of 118 and 274 nM, respectively. [18F]I was obtained with radiochemical yields of 73±12% (n=4, non-isolated) and a high radiochemical purity of > 98%. A logD7.4 value of 0.816 was achieved for [18F]I, which was 2-fold higher than that for [18F]FACH. By in vitro autoradiography in cryosections of the mouse kidney, nearly complete displacement of [18F]I by 10-5 M CHC-Na was observed. In vivo, similar to [18F]FACH, a low uptake of [18F]I in the brain without significant washout was found with an almost constant SUV of 0.15 between 15 and 60 min p.i.

Conclusion: Despite a higher lipophilicity of [18F]I compared to [18F]FACH, the brain uptake of [18F]I was in a similar low range. However, the high and specific uptake of the new radiotracer in the kidneys suggests suitability of [18F]I for detecting MCTs’ expression in vivo.

References: (1) Sadeghzadeh M, et al. J Label Compd Radiopharm.2019; 62: 411-424.